Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon, United States of America.
PLoS Pathog. 2011 Nov;7(11):e1002367. doi: 10.1371/journal.ppat.1002367. Epub 2011 Nov 10.
Primary infection with varicella zoster virus (VZV) results in varicella (more commonly known as chickenpox) after which VZV establishes latency in sensory ganglia. VZV can reactivate to cause herpes zoster (shingles), a debilitating disease that affects one million individuals in the US alone annually. Current vaccines against varicella (Varivax) and herpes zoster (Zostavax) are not 100% efficacious. Specifically, studies have shown that 1 dose of varivax can lead to breakthrough varicella, albeit rarely, in children and a 2-dose regimen is now recommended. Similarly, although Zostavax results in a 50% reduction in HZ cases, a significant number of recipients remain at risk. To design more efficacious vaccines, we need a better understanding of the immune response to VZV. Clinical observations suggest that T cell immunity plays a more critical role in the protection against VZV primary infection and reactivation. However, no studies to date have directly tested this hypothesis due to the scarcity of animal models that recapitulate the immune response to VZV. We have recently shown that SVV infection of rhesus macaques models the hallmarks of primary VZV infection in children. In this study, we used this model to experimentally determine the role of CD4, CD8 and B cell responses in the resolution of primary SVV infection in unvaccinated animals. Data presented in this manuscript show that while CD20 depletion leads to a significant delay and decrease in the antibody response to SVV, loss of B cells does not alter the severity of varicella or the kinetics/magnitude of the T cell response. Loss of CD8 T cells resulted in slightly higher viral loads and prolonged viremia. In contrast, CD4 depletion led to higher viral loads, prolonged viremia and disseminated varicella. CD4 depleted animals also had delayed and reduced antibody and CD8 T cell responses. These results are similar to clinical observations that children with agammaglobulinemia have uncomplicated varicella whereas children with T cell deficiencies are at increased risk of progressive varicella with significant complications. Moreover, our studies indicate that CD4 T cell responses to SVV play a more critical role than antibody or CD8 T cell responses in the control of primary SVV infection and suggest that one potential mechanism for enhancing the efficacy of VZV vaccines is by eliciting robust CD4 T cell responses.
初次感染水痘带状疱疹病毒(VZV)后会引发水痘(俗称水痘),此后 VZV 会在感觉神经节中潜伏。VZV 可能会重新激活,导致带状疱疹(带状疱疹),这是一种使人衰弱的疾病,仅在美国每年就影响 100 万人。目前针对水痘(Varivax)和带状疱疹(Zostavax)的疫苗并非 100%有效。具体来说,研究表明,1 剂 Varivax 可导致儿童出现罕见的突破性水痘,目前推荐使用 2 剂方案。同样,尽管 Zostavax 可使带状疱疹病例减少 50%,但仍有相当数量的受种者存在风险。为了设计更有效的疫苗,我们需要更好地了解针对 VZV 的免疫反应。临床观察表明,T 细胞免疫在预防 VZV 初次感染和重新激活方面起着更关键的作用。但是,由于缺乏能够重现 VZV 免疫反应的动物模型,迄今为止尚无研究直接检验这一假说。我们最近发现,SVV 感染恒河猴可模拟儿童初次 VZV 感染的特征。在这项研究中,我们使用该模型在未接种疫苗的动物中,实验确定了 CD4、CD8 和 B 细胞反应在 SVV 初次感染中的作用。本研究报告的数据表明,尽管 CD20 耗竭会导致针对 SVV 的抗体反应显著延迟和减少,但 B 细胞缺失并不会改变水痘的严重程度或 T 细胞反应的动力学/幅度。CD8 T 细胞缺失会导致病毒载量略高和持续时间较长的病毒血症。相比之下,CD4 耗竭会导致更高的病毒载量、更长的病毒血症和播散性水痘。CD4 耗尽的动物还具有延迟和减少的抗体和 CD8 T 细胞反应。这些结果与临床观察结果相似,即患有丙种球蛋白缺乏症的儿童患有单纯性水痘,而 T 细胞缺乏症的儿童则因严重的水痘并发症而面临更高的风险。此外,我们的研究表明,SVV 诱导的 CD4 T 细胞反应在控制 SVV 初次感染方面比抗体或 CD8 T 细胞反应更为关键,这表明增强 VZV 疫苗效果的一种潜在机制是引发强烈的 CD4 T 细胞反应。